United States· US:0456-2212_b4f9c587-d1eb-462b-bad2-ed0ce6d76c57
Fetzima
A levomilnacipran product containing levomilnacipran hydrochloride, registered in United States by Allergan, Inc.. The same ATC class is registered in 3 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Levomilnacipran is registered in 3 of 19 countries.
Countries holding a registration under ATC N06AX28 (levomilnacipran), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 1 of them publish a price we can compare per daily dose
Levomilnacipran · ATC N06AX28
3 / 19 countries
- Canada
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LEVOMILNACIPRAN HYDROCHLORIDE
- Manufacturer
- Allergan, Inc.
- Country
- United States (US)
- ATC code
- N06AX28
- ATC class
- Levomilnacipran
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc11045622123030 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0456-2212-30)
- ndc11045622129090 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0456-2212-90)
- ndc110456-2212-30
- ndc110456-2212-90
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
183 interactions on record for levomilnacipran.
Graded by severity as the source publishes them — 32 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Levomilnacipran · interactions on record
183 records
- 32 severe
- 151 moderate
Most severe, free to view
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- DolasetronA04AA04severe
- PalonosetronA04AA05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Levomilnacipran in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0d0c60b7-63d6-4d3d-b255-c232de40df1a GET /v1/drugs/0d0c60b7-63d6-4d3d-b255-c232de40df1a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "120",
"substance": "LEVOMILNACIPRAN HYDROCHLORIDE",
"productndc": "0456-2212",
"dosage_form": "CAPSULE, EXTENDED RELEASE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA204168",
"marketing_category": "NDA"
}See everything about levomilnacipran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.